-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target

Benzinga·10/20/2026 11:00:02
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Braveheart Bio (NASDAQ:BRVE) with a Overweight and maintains $40 price target.